Page last updated: 2024-12-09

[5,7-bis(trifluoromethyl)-1,8-naphthyridin-2-yl]hydrazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

**[5,7-bis(trifluoromethyl)-1,8-naphthyridin-2-yl]hydrazine** is a synthetic organic compound with a complex structure. It consists of:

* **1,8-naphthyridine:** A bicyclic heterocyclic compound with a nitrogen atom at the 1 and 8 positions.
* **Trifluoromethyl groups (CF3):** Attached to the 5 and 7 positions of the naphthyridine ring.
* **Hydrazine group (NH2NH2):** Attached to the 2 position of the naphthyridine ring.

**Importance for Research:**

The compound's importance lies in its potential applications in various research areas, including:

* **Medicinal Chemistry:**
* **Antimicrobial activity:** The presence of trifluoromethyl groups and the naphthyridine core structure can contribute to antimicrobial properties. These groups often enhance drug efficacy and stability.
* **Anti-cancer activity:** Research suggests that hydrazine derivatives can exhibit anti-cancer activity by interfering with cell growth and proliferation.
* **Other therapeutic applications:** The specific structural features of this compound might be explored for developing drugs targeting other diseases, such as Alzheimer's disease or Parkinson's disease.

* **Material Science:**
* **Organic electronics:** The electron-withdrawing nature of trifluoromethyl groups and the planar structure of the naphthyridine ring could make this compound suitable for use in organic electronic devices, such as organic light-emitting diodes (OLEDs).
* **Organic photovoltaics:** The compound's ability to absorb light and transfer electrons could be relevant for developing solar cells.

* **Chemical Synthesis:**
* **Building block:** This compound can serve as a versatile building block for synthesizing more complex molecules with specific functionalities.
* **Catalyst design:** The compound's unique structural characteristics might lead to the development of novel catalysts for various chemical reactions.

**Current Research:**

Research on [5,7-bis(trifluoromethyl)-1,8-naphthyridin-2-yl]hydrazine and its derivatives is still ongoing. Scientists are exploring its potential applications in the areas mentioned above and investigating its biological and chemical properties in detail.

**Note:** It's important to remember that this compound is a research tool and its safety and efficacy have not been fully established.

Cross-References

ID SourceID
PubMed CID2764722
CHEMBL ID1353139
CHEBI ID109562
SCHEMBL ID6712592

Synonyms (19)

Synonym
HMS2638L07
MLS000694594
7-hydrazino-2,4-bis(trifluoromethyl)[1,8]naphthyridine
smr000333268
BIONET2_000096
CHEBI:109562
HMS1364E08
AKOS005074061
[5,7-bis(trifluoromethyl)-1,8-naphthyridin-2-yl]hydrazine
HMS3361C19
(5,7-bis-trifluoromethyl-[1,8]naphthyridin-2-yl)-hydrazine
241488-23-3
10D-016
7-hydrazinyl-2,4-bis(trifluoromethyl)-1,8-naphthyridine
SCHEMBL6712592
CHEMBL1353139
Q27188704
DTXSID501203280
mfcd00140157
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
naphthyridine derivativeAny organonitrogen heterocyclic compound that is a derivative of a naphthyridine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acid sphingomyelinaseHomo sapiens (human)Potency31.622814.125424.061339.8107AID504937
thioredoxin reductaseRattus norvegicus (Norway rat)Potency56.23410.100020.879379.4328AID588456
phosphopantetheinyl transferaseBacillus subtilisPotency56.23410.141337.9142100.0000AID1490
TDP1 proteinHomo sapiens (human)Potency23.72460.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency7.07950.180013.557439.8107AID1460
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency19.95260.707912.194339.8107AID720542
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.18380.011212.4002100.0000AID1030
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency35.48130.035520.977089.1251AID504332
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency39.50680.036619.637650.1187AID2100
chromobox protein homolog 1Homo sapiens (human)Potency70.79460.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency7.30780.00419.984825.9290AID504444
importin subunit beta-1 isoform 1Homo sapiens (human)Potency100.00005.804836.130665.1308AID540263
ras-related protein Rab-9AHomo sapiens (human)Potency5.62340.00022.621531.4954AID485297
snurportin-1Homo sapiens (human)Potency100.00005.804836.130665.1308AID540263
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency12.58930.00798.23321,122.0200AID2551
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency31.62280.00419.962528.1838AID2675
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency17.78280.025911.239831.6228AID602313
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]